Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2024

08.12.2022 | Maternal-fetal Medicine

Effect of obesity on the time to a successful medical abortion with misoprostol in first-trimester missed abortion

verfasst von: Zekiye Soykan Sert, Mete Bertizlioğlu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the efficacy of misoprostol used in first-trimester abortion in obese women and to determine whether obesity is associated with time to a successful medical abortion.

Methods

The records of patients diagnosed with missed abortion at our clinic between 2018 and 2021 were retrospectively reviewed. All women aged 18 to 45 years who were diagnosed with missed abortion in the first trimester and treated with misoprostol were included in the study. The cases were divided into two groups: obese (body mass index [BMI] ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2). First, they were simultaneously administered 200 μg misoprostol orally and 400 μg vaginally. After the first misoprostol administration, the dose was repeated vaginally at 400 μg every three hours if necessary. The effect of obesity on the time taken to achieve a medical abortion was evaluated.

Results

A successful medical abortion occurred in 45.2% of the women in the obese group and 69.0% of those in the non-obese group. The time to uterine evacuation was 8.24 ± 4.03 h in the obese group and 6.35 ± 3.54 h in the non-obese group. The relationship between obesity and time to a successful medical abortion was evaluated using the Kaplan–Meier curve, which showed a significant difference between the two groups (p = 0.028).

Conclusion

Our findings show that obesity affects time to a successful medical abortion. In addition, the rate of successful medical abortion after misoprostol administration was lower in the obese women.
Literatur
1.
Zurück zum Zitat Rottenstreich A, Levin G, Ben Shushan A et al (2019) The role of repeat misoprostol dose in the management of early pregnancy failure. Arch Gynecol Obstet 300(5):1287–1293CrossRefPubMed Rottenstreich A, Levin G, Ben Shushan A et al (2019) The role of repeat misoprostol dose in the management of early pregnancy failure. Arch Gynecol Obstet 300(5):1287–1293CrossRefPubMed
2.
Zurück zum Zitat Bolnga JW, Lufele E, Teno M et al (2021) Incidence of self-induced abortion with misoprostol, admitted to a provincial hospital in papua New Guinea: a prospective observational study. Aust N Z J Obstet Gynaecol 61(6):955–960CrossRefPubMed Bolnga JW, Lufele E, Teno M et al (2021) Incidence of self-induced abortion with misoprostol, admitted to a provincial hospital in papua New Guinea: a prospective observational study. Aust N Z J Obstet Gynaecol 61(6):955–960CrossRefPubMed
3.
Zurück zum Zitat ACOG Practice Bulletin No (2018) 200: Early Pregnancy loss. Obstet Gynecol 132(5):e197–e207CrossRef ACOG Practice Bulletin No (2018) 200: Early Pregnancy loss. Obstet Gynecol 132(5):e197–e207CrossRef
5.
Zurück zum Zitat Morrish GA, Pai MP, Green B (2011) The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 7(6):697–706CrossRefPubMed Morrish GA, Pai MP, Green B (2011) The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 7(6):697–706CrossRefPubMed
6.
Zurück zum Zitat Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87CrossRefPubMed Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87CrossRefPubMed
7.
Zurück zum Zitat Wu HL, Marwah S, Wang P et al (2017) Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis. Sci Rep 7(1):1664CrossRefPubMedPubMedCentral Wu HL, Marwah S, Wang P et al (2017) Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis. Sci Rep 7(1):1664CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Marwah S, Gupta S, Batra NP et al (2016) A Comparative study to evaluate the efficacy of vaginal vs oral prostaglandin e1 analogue (Misoprostol) in management of first trimester missed abortion. J Clin Diagn Res 10(5):14–18 Marwah S, Gupta S, Batra NP et al (2016) A Comparative study to evaluate the efficacy of vaginal vs oral prostaglandin e1 analogue (Misoprostol) in management of first trimester missed abortion. J Clin Diagn Res 10(5):14–18
9.
Zurück zum Zitat Dunford A, Fyfe R (2018) Combination therapy with mifepristone and misoprostol for the management of first trimester miscarriage: improved success. Aust N Z Coll Obstet Gynaecol 58(4):438–442CrossRef Dunford A, Fyfe R (2018) Combination therapy with mifepristone and misoprostol for the management of first trimester miscarriage: improved success. Aust N Z Coll Obstet Gynaecol 58(4):438–442CrossRef
10.
Zurück zum Zitat Redling K, Schaedelin S, Huhn EA et al (2019) Efficacy and safety of misoprostol vaginal insert vs oral misoprostol for induction of labor. J Perinat Med 47(2):176–182CrossRefPubMed Redling K, Schaedelin S, Huhn EA et al (2019) Efficacy and safety of misoprostol vaginal insert vs oral misoprostol for induction of labor. J Perinat Med 47(2):176–182CrossRefPubMed
11.
Zurück zum Zitat Behnamfar F, Mahdian M, Rahimi F et al (2013) Misoprostol abortion: Ultrasonography versus Beta-hCG testing for verification of effectiveness. Pak J Med Sci 29:1367–1370CrossRefPubMedPubMedCentral Behnamfar F, Mahdian M, Rahimi F et al (2013) Misoprostol abortion: Ultrasonography versus Beta-hCG testing for verification of effectiveness. Pak J Med Sci 29:1367–1370CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Yilmaz B, Kelekci S, Ertas IE et al (2007) Randomized comparison of second trimester pregnancy termination utilizing saline moistened or dry misoprostol. Arch Gynecol Obstet 276:511–516CrossRefPubMed Yilmaz B, Kelekci S, Ertas IE et al (2007) Randomized comparison of second trimester pregnancy termination utilizing saline moistened or dry misoprostol. Arch Gynecol Obstet 276:511–516CrossRefPubMed
13.
Zurück zum Zitat Wong KS, Ngai CS, Yeo EL et al (2000) A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomized comparative trial. Hum Reprod 15:709–712CrossRefPubMed Wong KS, Ngai CS, Yeo EL et al (2000) A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomized comparative trial. Hum Reprod 15:709–712CrossRefPubMed
14.
Zurück zum Zitat Bhattacharjee N, Saha SP, Ganguly RP et al (2012) A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination. Arch Gynecol Obstet 285:311–316CrossRefPubMed Bhattacharjee N, Saha SP, Ganguly RP et al (2012) A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination. Arch Gynecol Obstet 285:311–316CrossRefPubMed
15.
Zurück zum Zitat Allameh Z, Goharian M, Eslamian M (2020) Effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. Int J Gynaecol Obstet 151(2):214–218CrossRefPubMed Allameh Z, Goharian M, Eslamian M (2020) Effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. Int J Gynaecol Obstet 151(2):214–218CrossRefPubMed
16.
Zurück zum Zitat Tasnee S, Gul MS, Navid S et al (2014) Efficacy and safety of misoprostolin missed miscarriage in terms of blood loss. RMJ 39(3):314–318 Tasnee S, Gul MS, Navid S et al (2014) Efficacy and safety of misoprostolin missed miscarriage in terms of blood loss. RMJ 39(3):314–318
17.
Zurück zum Zitat Seyam YS, Flamerzi MA, Abdallah MM et al (2007) Vaginal misoprostol in the management of first trimester non-viable pregnancy. Qa Med J 17:14–19 Seyam YS, Flamerzi MA, Abdallah MM et al (2007) Vaginal misoprostol in the management of first trimester non-viable pregnancy. Qa Med J 17:14–19
18.
Zurück zum Zitat El Sokkary HH (2016) Comparison Between Sublingual and Vaginal Administration of Misoprostol in Management of Missed Abortion. J Obstet Gynaecol India 66(Suppl 1):24–29CrossRefPubMed El Sokkary HH (2016) Comparison Between Sublingual and Vaginal Administration of Misoprostol in Management of Missed Abortion. J Obstet Gynaecol India 66(Suppl 1):24–29CrossRefPubMed
19.
Zurück zum Zitat Soni S, Pappas K, Lesser ML et al (2020) Is vaginal misoprostol more effective than oral misoprostol for cervical ripening in obese women? J Matern Fetal Neonatal Med 33(20):3476–3483CrossRefPubMed Soni S, Pappas K, Lesser ML et al (2020) Is vaginal misoprostol more effective than oral misoprostol for cervical ripening in obese women? J Matern Fetal Neonatal Med 33(20):3476–3483CrossRefPubMed
20.
Zurück zum Zitat Wolfe KB, Rossi RA, Warshak CR (2011) The effect of maternal obesity on the rate of failed induction of labor. Am J Obstet Gynecol 205(2):128.e1–7CrossRefPubMed Wolfe KB, Rossi RA, Warshak CR (2011) The effect of maternal obesity on the rate of failed induction of labor. Am J Obstet Gynecol 205(2):128.e1–7CrossRefPubMed
21.
Zurück zum Zitat Lassiter JR, Holliday N, Lewis DF et al (2016) Induction of labor with an unfavorable cervix: how does BMI affect success. J Matern Fetal Med 29(18):3000–3002CrossRef Lassiter JR, Holliday N, Lewis DF et al (2016) Induction of labor with an unfavorable cervix: how does BMI affect success. J Matern Fetal Med 29(18):3000–3002CrossRef
22.
Zurück zum Zitat Stefely E, Warshak CR (2019) Contraction frequency after administration of misoprostol in obese versus nonobese women. J Matern Fetal Neonatal Med 32(21):3526–3530CrossRefPubMed Stefely E, Warshak CR (2019) Contraction frequency after administration of misoprostol in obese versus nonobese women. J Matern Fetal Neonatal Med 32(21):3526–3530CrossRefPubMed
23.
Zurück zum Zitat Reeves MF, Monmaney JA, Creinin MD (2016) Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception 93(2):119–125CrossRefPubMed Reeves MF, Monmaney JA, Creinin MD (2016) Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception 93(2):119–125CrossRefPubMed
Metadaten
Titel
Effect of obesity on the time to a successful medical abortion with misoprostol in first-trimester missed abortion
verfasst von
Zekiye Soykan Sert
Mete Bertizlioğlu
Publikationsdatum
08.12.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-022-06875-9

Weitere Artikel der Ausgabe 1/2024

Archives of Gynecology and Obstetrics 1/2024 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.